Scarica l'app Stockscreener
1.40
0.35%
-0.02
Dopo l'orario di chiusura:
1.38
-0.02
-1.43%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMEA Giù?
Forum
Previsione
Precedente Chiudi:
$1.42
Aprire:
$1.44
Volume 24 ore:
1.34M
Relative Volume:
0.91
Capitalizzazione di mercato:
$101.22M
Reddito:
-
Utile/perdita netta:
$-61.80M
Rapporto P/E:
-0.9212
EPS:
-1.5197
Flusso di cassa netto:
$-70.37M
1 W Prestazione:
+15.98%
1M Prestazione:
-25.13%
6M Prestazione:
+32.24%
1 anno Prestazione:
-4.39%
Intervallo 1D:
$1.32
$1.445
Intervallo di 1 settimana:
$1.22
$1.464
Portata 52W:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Nome
Biomea Fusion Inc
Settore
Industria
Telefono
(650) 980-9099
Indirizzo
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.40 | 102.67M | 0 | -61.80M | -70.37M | -1.5197 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-13 | Iniziato | Rodman & Renshaw | Buy |
| 2025-08-28 | Iniziato | Jefferies | Buy |
| 2025-06-03 | Ripresa | Piper Sandler | Overweight |
| 2024-10-09 | Iniziato | Edward Jones | Buy |
| 2024-09-27 | Aggiornamento | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | Aggiornamento | Truist | Hold → Buy |
| 2024-08-29 | Iniziato | CapitalOne | Overweight |
| 2024-06-11 | Downgrade | Truist | Buy → Hold |
| 2024-06-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-04-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-06 | Iniziato | Truist | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Outperform |
| 2023-06-26 | Downgrade | Jefferies | Buy → Hold |
| 2023-05-12 | Iniziato | Barclays | Overweight |
| 2023-03-29 | Reiterato | Oppenheimer | Outperform |
| 2023-03-28 | Reiterato | H.C. Wainwright | Buy |
| 2023-02-24 | Iniziato | Citigroup | Buy |
| 2022-06-02 | Ripresa | H.C. Wainwright | Buy |
| 2022-01-12 | Iniziato | H.C. Wainwright | Buy |
| 2021-12-17 | Iniziato | Oppenheimer | Outperform |
| 2021-05-11 | Iniziato | JP Morgan | Overweight |
| 2021-05-11 | Iniziato | Jefferies | Buy |
| 2021-05-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Biomea Fusion Inc Borsa (BMEA) Ultime notizie
BMEA Stock Price, Quote & Chart | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion, Inc.Common Stock (NQ: BMEA - FinancialContent
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Biomea Fusion to Participate at Upcoming Investor Conferences - marketscreener.com
Analyst Reiterates Buy on Biomea Fusion, Maintains $4 Price Target Amid Advancing Metabolic Pipeline - TipRanks
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Biomea Fusion completes Icovamenib chronic tox studies and posts 52-week follow-up in diabetes pipeline - Traders Union
Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism - ChartMill
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights - Investing News Network
BIOMEA FUSION ($BMEA) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Biomea Fusion 4Q Loss/Shr 17c >BMEA - Moomoo
Biomea Fusion Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biomea Fusion, Inc. Q1 2026: Net loss $(12.4)M, EPS $(0.17) — 10-Q Summary - TradingView
Biomea Fusion Q1 net loss narrows as expenses fall - TradingView
Biomea Fusion (BMEA) trims Q1 2026 loss but flags cash runway only into early 2027 - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biomea Fusion (Nasdaq: BMEA) cuts Q1 2026 loss while advancing diabetes and obesity pipeline - Stock Titan
Biomea diabetes drug shows 52% C-peptide boost at 12 weeks - Stock Titan
BMEA.O Technical Analysis & Stock Price Forecast - Intellectia AI
BMEA Technical Analysis | Trend, Signals & Chart Patterns | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Icovamenib boosts C-peptide secretion in 52-week diabetes trial - Traders Union
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Citizens Initiates Coverage of Biomea Fusion (BMEA) with Market Outperform Recommendation - MSN
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - The Manila Times
Biomea Fusion to present new icovamenib data at American Diabetes Association event - Traders Union
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Biomea Fusion Announces Late-Breaking Poster Presentations on Icovamenib at ADA 86th Scientific Sessions - Quiver Quantitative
Three diabetes studies put Biomea's icovamenib in ADA late-breakers - Stock Titan
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association ... - Caledonian Record
Biomea Fusion Announces Poster Presentations of Icovamenib - GlobeNewswire
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - Yahoo Finance
Citizens JMP Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $9 - Moomoo
Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential By Investing.com - Investing.com South Africa
Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential - Investing.com Nigeria
Biomea Fusion Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
U.S. Earnings Preview: After Market Close May 1 - Moomoo
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
BMEA Should I Buy - Intellectia AI
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - MarketBeat
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 DiabetesSlideshow (NASDAQ:BMEA) 2026-04-28 - Seeking Alpha
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital - MarketBeat
Biomea Fusion Reports Positive Phase 2 T1D Trial Results - TipRanks
Biomea Fusion | 8-K: Current report - Moomoo
Phase 2 icovamenib T1D data from Biomea Fusion (NASDAQ: BMEA) show 52% C-peptide gain - Stock Titan
Biomea Fusion Is Maintained at Buy by D. Boral Capital - Moomoo
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - markets.businessinsider.com
Biomea reports positive type 1 diabetes trial results By Investing.com - Investing.com Canada
Biomea reports positive type 1 diabetes trial results - Investing.com UK
Biomea Fusion Inc Azioni (BMEA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):